Medimmune Limited

Philip Newton

Feenagh Keyes

Sven Nylander

Mark Penney

Tord Inghardt

Andrew Grier Buchanan

Claire Louise Dobson

David Fairman

Sadhana Podichetty

Peter Thornton

Ian Gurrell

Richard Williams

Steven Godfrey Lane

Martin Schwickart

Ann-Charlott Steffen

Andrew Buchanan

The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.

Antibodies to ticagrelor and methods of use

The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Nucleic acids encoding anti-PAR2 antibodies and uses thereof

Anti-PAR2 antibodies and uses thereof

The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.

Anti-IL-18 antibodies and their uses

Growing community of inventors

Cambridge, United Kingdom

Philip Newton